These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 2784143)
1. Protective effects of IL-1 on human hematopoietic progenitor cells treated in vitro with 4-hydroperoxycyclophosphamide. Moreb J; Zucali JR; Gross MA; Weiner RS J Immunol; 1989 Mar; 142(6):1937-42. PubMed ID: 2784143 [TBL] [Abstract][Full Text] [Related]
2. The role of interleukin 3 and interleukin 6 in the protection from 4-hydroperoxycyclophosphamide and the proliferation of early human hematopoietic progenitor cells. Moreb J; Zucali JR; Weiner RS Exp Hematol; 1989 Nov; 17(10):1022-7. PubMed ID: 2806435 [TBL] [Abstract][Full Text] [Related]
3. TGF-beta 3 protects normal human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide in vitro. Lemoli RM; Strife A; Clarkson BD; Haley JD; Gulati SC Exp Hematol; 1992 Dec; 20(11):1252-6. PubMed ID: 1493854 [TBL] [Abstract][Full Text] [Related]
4. In vitro sensitivity of human hematopoietic progenitor cells to 4-hydroperoxycyclophosphamide. Ratajczak MZ; Ratajczak J; Kuczynski W; Light B; Lusk EJ; Gewirtz AM Exp Hematol; 1993 Dec; 21(13):1663-7. PubMed ID: 8243568 [TBL] [Abstract][Full Text] [Related]
5. Role of aldehyde dehydrogenase in the protection of hematopoietic progenitor cells from 4-hydroperoxycyclophosphamide by interleukin 1 beta and tumor necrosis factor. Moreb J; Zucali JR; Zhang Y; Colvin MO; Gross MA Cancer Res; 1992 Apr; 52(7):1770-4. PubMed ID: 1551107 [TBL] [Abstract][Full Text] [Related]
6. Protection of cells capable of reconstituting long-term bone marrow stromal cultures from 4-hydroperoxycyclophosphamide by interleukin 1 and tumor necrosis factor. Zucali JR; Moreb J; Bain C Exp Hematol; 1992 Sep; 20(8):969-73. PubMed ID: 1505642 [TBL] [Abstract][Full Text] [Related]
7. Role for aldehyde dehydrogenase in survival of progenitors for murine blast cell colonies after treatment with 4-hydroperoxycyclophosphamide in vitro. Sahovic EA; Colvin M; Hilton J; Ogawa M Cancer Res; 1988 Mar; 48(5):1223-6. PubMed ID: 3342403 [TBL] [Abstract][Full Text] [Related]
8. Contrasting mechanisms of the myeloprotective effects of interleukin-1 against ionizing radiation and cytotoxic 5-fluorouracil. Neta R; Keller JR; Ali N; Blanchette F; Dubois CM Radiat Res; 1996 May; 145(5):624-31. PubMed ID: 8619029 [TBL] [Abstract][Full Text] [Related]
9. Use of long-term human marrow cultures to demonstrate progenitor cell precursors in marrow treated with 4-hydroperoxycyclophosphamide. Winton EF; Colenda KW Exp Hematol; 1987 Jul; 15(6):710-4. PubMed ID: 3595769 [TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of 4-hydroperoxycyclophosphamide for the blast progenitors of acute myeloblastic leukemia. Nara N; Suzuki T; Yamashita Y; Murohashi I; Aoki N Cancer Res; 1988 May; 48(9):2348-52. PubMed ID: 3162711 [TBL] [Abstract][Full Text] [Related]
11. Characterization of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide. Douay L; Giarratana MC; Labopin M; Bardinet D; Bouchet S; Gorin NC Bone Marrow Transplant; 1995 May; 15(5):769-75. PubMed ID: 7670404 [TBL] [Abstract][Full Text] [Related]
12. Survival of highly proliferative colony forming cells after treatment of bone marrow cells with 4-hydroperoxycyclophosphamide. Komatsu N; Suda T; Suda J; Miura Y Cancer Res; 1987 Dec; 47(23):6371-6. PubMed ID: 3677081 [TBL] [Abstract][Full Text] [Related]
13. Normal blast colony formation: an in vitro tool for monitoring human bone marrow 'purging'. Degliantoni G; Mangoni L; Rizzoli V Bone Marrow Transplant; 1986 Dec; 1(2):209-13. PubMed ID: 3332133 [TBL] [Abstract][Full Text] [Related]
14. Human multilineage progenitor cell sensitivity to 4-hydroperoxycyclophosphamide. Rowley SD; Colvin OM; Stuart RK Exp Hematol; 1985 May; 13(4):295-8. PubMed ID: 3987832 [TBL] [Abstract][Full Text] [Related]
15. Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants. Douay L; Hu C; Giarratana MC; Gorin NC Semin Oncol; 1994 Oct; 21(5 Suppl 11):16-20. PubMed ID: 7973773 [TBL] [Abstract][Full Text] [Related]
16. Effect of stem cell factor (c-kit ligand), granulocyte-macrophage colony stimulating factor and interleukin 3 on hematopoietic progenitors in human long-term bone marrow cultures. Lemoli RM; Gulati SC Stem Cells; 1993 Sep; 11(5):435-44. PubMed ID: 7694721 [TBL] [Abstract][Full Text] [Related]
17. Interleukin-11 stimulates the proliferation of human hematopoietic CD34+ and CD34+CD33-DR- cells and synergizes with stem cell factor, interleukin-3, and granulocyte-macrophage colony-stimulating factor. Lemoli RM; Fogli M; Fortuna A; Motta MR; Rizzi S; Benini C; Tura S Exp Hematol; 1993 Dec; 21(13):1668-72. PubMed ID: 7694867 [TBL] [Abstract][Full Text] [Related]
18. The effects of acetaldophosphamide, a novel stable aldophosphamide analogue, on normal human and leukemic progenitor cells in vitro: implications for use in bone marrow purging. Beran M; Andersson BS; Wang Y; McCredie KB; Farquhar D Cancer Res; 1988 Jan; 48(2):339-45. PubMed ID: 3275495 [TBL] [Abstract][Full Text] [Related]
19. The effects of tumor necrosis factor-alpha on early human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide. Moreb J; Zucali JR; Rueth S Blood; 1990 Aug; 76(4):681-9. PubMed ID: 2383651 [TBL] [Abstract][Full Text] [Related]
20. Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin 1: protection from hematological and nonhematological toxicities. Damia G; Komschlies KL; Futami H; Back T; Gruys ME; Longo DL; Keller JR; Ruscetti FW; Wiltrout RH Cancer Res; 1992 Aug; 52(15):4082-9. PubMed ID: 1638519 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]